We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
30/9/2016 09:06 | But how do we as minnows cope with the fact that Jim Mellon seems happy with the thought of us accepting any deal that values our shares at £3 plus? For goodness sake the share price hit £4 here three years ago! As I mentioned previously, I have no desire to have a stake in Summit via Sarapta shares. I do hope Glyn has SUMMthing up his sleeve that doesn't put us all at the mercy of anything to do with Sarepta. | hugus maximus | |
30/9/2016 00:06 | looking better | football | |
29/9/2016 23:34 | Hopefully other bigger fish than Sarepta would be prepared to match their offer or beat it ... with cash. Why wait to acquire SRPT afterwards, with its less than impressive in tests drug, when you can have Summit's potential blockbuster for less ? | luminoso | |
29/9/2016 23:10 | Can't rule out a takeover by SRPT, they could try with a share only offer. Asset for shares helps their books look good. I got a 3x value for PLE, and sold it before the drop. Not sure what our value is today, I've heard many figures banded about for the future. I would be happy with the equivalent of £6 a share in stock. We would then share in the profits of THE main DMD research company in the world. That would place SRPT in a prime position for a takeover too. | sorrento06 | |
29/9/2016 21:05 | Oh well, my predictive powers are clearly defective ! Think Kristini is right, the Placing is looming and holding the price back, despite the Sarepta interest. | luminoso | |
29/9/2016 18:46 | Catabasis Pharmaceuticals and Sarepta Therapeutics Announce a Joint Research Collaboration in Duchenne Muscular Dystrophy Edit:Many postings this may have been posted earlier | chrisatrdg | |
29/9/2016 17:43 | Or a complete take over of course ....... | kristini2 | |
29/9/2016 16:18 | A pacing highly likely, a partnership preferable but they'll burn through the cash soon so they need to raise money, so one or the other The share price will be factoring in a placing and hence is probably being held back because of this | kristini2 | |
29/9/2016 16:07 | Question is partnership on RDZ, EZD, or both ?! | luminoso | |
29/9/2016 16:04 | As it happens, I did hear from Glyn earlier today and he did say that they would get funding either from a placing or a partnership. The latter looks much more likely to me. | someuwin | |
29/9/2016 15:54 | RG still dumping into strength ? | luminoso | |
29/9/2016 15:51 | agree. Cash only please. nasdaq will mysteriously wake up again around 4.30pm IMO. | luminoso | |
29/9/2016 15:49 | But PLEASE don't make me ever have shares in Sarepta ... :-( NASDAQ gone back to sleep. | hugus maximus | |
29/9/2016 15:39 | So do we think Sarepta will enter a strategic partneship with SUMM? Providing a big chunk of cash upfront to buy into a percentage of future revenues. edit: they have just raised 300m haven't they? | someuwin | |
29/9/2016 15:10 | Expect more lurches downwards before 4.30pm and then we should see the real rise, IMO. trying to be wary of any more toilet references !! | luminoso | |
29/9/2016 15:07 | Glued to your screen! Too much information | freedosh | |
29/9/2016 15:05 | Too true, freedosh ! No I am glued to my screen. But US traders seem to have been caught with their pants down initially !! Now waking up. | luminoso | |
29/9/2016 15:04 | Pieces of 8 (squid)? | freedosh | |
29/9/2016 15:03 | Still in the loo, Luminosa? Could be C(offee)Difficile | freedosh |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions